Previous Close | 14.00 |
Open | 14.00 |
Bid | 17.40 |
Ask | 17.75 |
Strike | 60.00 |
Expire Date | 2025-01-17 |
Day's Range | 14.00 - 14.00 |
Contract Range | N/A |
Volume | |
Open Interest | 299 |
AstraZeneca CEO Pascal Soriot joined Yahoo Finance to discuss the company's earnings today.
Fusion (FUSN) is expected to provide updates regarding the developmental program of its lead candidate, FPI-2265, for prostate cancer in the first-quarter earnings release.
AstraZeneca stock bolted higher Thursday — and is now within striking distance of a breakout — after its cancer drugs propelled a sales beat.